Kailera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to advancing a broad portfolio of next-generation therapies for obesity and metabolic disorders. The company's pipeline is built around several differentiated incretin-based programs designed to offer improved efficacy and convenience for patients. Kailera's lead assets include KLR-102, a long-acting GLP-1/GIP/glucagon receptor tri-agonist currently in clinical development, as well as oral small molecule GLP-1 receptor agonists. These programs aim to address the global obesity epidemic by providing potent weight loss solutions and managing comorbid conditions such as type 2 diabetes and cardiovascular disease. Formed with a significant capital commitment and a suite of licensed assets from Jiangsu Hengrui Pharmaceuticals, Kailera is led by a management team with extensive experience in the biotechnology and metabolic sectors. The company is positioned to compete in the rapidly expanding incretin market by leveraging its diverse clinical-stage portfolio and focusing on the next wave of innovation in metabolic health.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!